Form 4: RxSight Director Shweta Maniar Receives Equity Grant of 10,752 Restricted Stock Units

RxSight, Inc. Director Shweta Maniar was granted 10,752 restricted stock units (RSUs) as part of her compensation, aligning her interests with shareholders.

Summary

• RxSight, Inc. Director Shweta Maniar reported the acquisition of 10,752 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on June 3, 2025, which is also designated as the Date of Grant for these RSUs.
• Each RSU represents a contingent right to receive one share of RxSight, Inc. Common Stock.
• Following this transaction, Ms. Maniar beneficially owns a total of 18,135 shares of Common Stock.
• The RSUs are subject to vesting, with 100% vesting on the earlier of the one-year anniversary of the grant date (June 3, 2025) or the date immediately prior to the next annual meeting of stockholders, provided Ms. Maniar continues as an Outside Director.

Sentiment

Score: 6

Explanation: Slightly positive as it represents standard equity compensation for a director, aligning interests with shareholders, which is a positive governance practice. No negative implications are present, and it's a routine, expected event.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Shweta Maniar aligns her long-term interests with those of the company's shareholders, promoting shared incentives for value creation.
• Equity compensation is a standard and effective practice for retaining and incentivizing key personnel, including independent directors, ensuring their commitment to the company's success.

Future Outlook

The granted Restricted Stock Units (RSUs) are expected to vest on the earlier of June 3, 2026 (one-year anniversary of grant) or the date immediately prior to the next annual meeting of stockholders, contingent on the director's continued service as an Outside Director.

Industry Context

This is a routine equity compensation grant to a director, a common practice across publicly traded companies to align management and board interests with shareholder value creation. Such grants are a standard component of director compensation packages in the U.S. corporate landscape.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a widely adopted practice among U.S. public companies, including those in the medical technology and ophthalmology sectors like RxSight.
• The vesting schedule, typically over one year or until the next annual meeting, is standard for annual director equity grants, comparable to practices at companies such as Alcon (ALC) or Bausch + Lomb (BLCO) for their non-employee directors, reflecting common corporate governance principles.

Corporate Governance

Related Party Transactions

• The grant of 10,752 Restricted Stock Units (RSUs) to Director Shweta Maniar constitutes a related party transaction, as it is a form of compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director is intended to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic oversight.
• Employees: No direct impact on employees is mentioned in this specific filing.

Next Steps

• The 10,752 Restricted Stock Units (RSUs) are expected to vest on the earlier of June 3, 2026, or the date immediately prior to the next annual meeting of stockholders, subject to the director's continued service.

Key Dates

Recommendation

Keywords

RxSight, RXST, Form 4, SEC filing, insider transaction, restricted stock units, RSUs, equity compensation, director compensation, beneficial ownership